A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

NCT05198752 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Neoantigen mRNA Personalised Cancer SW1115C3

Sponsor

Stemirna Therapeutics